Evidence map›Paper›PMID 32042038›Full record

Trial reportScientific reports2020

Emotions and brain function are altered up to one month after a single high dose of psilocybin.

Frederick S Barrett, Manoj K Doss, Nathan D Sepeda, James J Pekar, Roland R Griffiths

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07610135 (PRISMatic), which is not on this map. Cited by 164 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07610135 phase1 / phase2recruitingnot on this mapstarted 2026, after this paper: background citation

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

TypeinterventionalSponsorJohns Hopkins UniversityRan2026 to 2028Enrolled20ConditionsMood (Psychological Function), Well Being, Mood, HealthyArmsPsilocybin, Pimavanserin, Inactive Placebo
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Default Mode Network Modulation by Psychedelics: A Systematic Review.The international journal of neuropsychopharmacology · 2023
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Trial
  20. Trial

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Frederick S BarrettCenter for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA. fbarrett@jhmi.edu.ORCID http://orcid.org/0000-0001-7443-3237
Manoj K DossCenter for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.
Nathan D SepedaCenter for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.
James J PekarF.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, 21205, USA.
Roland R GriffithsCenter for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.

Funding

TR&D 4: Algorithms for functional and anatomical brain analysisP41EB015909 · NIBIB · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI VAN ZIJL, PETER CM · 2012 to 2020
$13.1M
HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Human Clinical Pharmacology of Emerging Drugs of Abuse (Club Drugs)R01DA003889 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GRIFFITHS, ROLAND R · 1985 to 2017
$7.6M
Measurement of persisting changes in emotional brain functioning produced by psilocybinR03DA042336 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BARRETT, FREDERICK STREETER · 2016 to 2016
$260k
NIBIB NIH HHS P41 EB015909NIDA NIH HHS R01 DA003889NIDA NIH HHS R03 DA042336
6 · The paper itself

Abstract

Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli. However, no study has investigated the long-term, enduring impact of psilocybin on negative affect and associated brain function. Twelve healthy volunteers (7F/5M) completed an open-label pilot study including assessments 1-day before, 1-week after, and 1-month after receiving a 25 mg/70 kg dose of psilocybin to test the hypothesis that psilocybin administration leads to enduring changes in affect and neural correlates of affect. One-week post-psilocybin, negative affect and amygdala response to facial affect stimuli were reduced, whereas positive affect and dorsal lateral prefrontal and medial orbitofrontal cortex responses to emotionally-conflicting stimuli were increased. One-month post-psilocybin, negative affective and amygdala response to facial affect stimuli returned to baseline levels while positive affect remained elevated, and trait anxiety was reduced. Finally, the number of significant resting-state functional connections across the brain increased from baseline to 1-week and 1-month post-psilocybin. These preliminary findings suggest that psilocybin may increase emotional and brain plasticity, and the reported findings support the hypothesis that negative affect may be a therapeutic target for psilocybin.

Indexed as

AdultAmygdalaBrain MappingCerebral CortexEmotionsFemaleFollow-Up StudiesHallucinogensHealthy VolunteersHumansMagnetic Resonance ImagingMaleNerve NetNeuronal PlasticityPilot ProjectsPsilocybinHallucinogensPsilocybin

Identifiers

PMID32042038
PMCPMC7010702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.